Sanofi-Aventis SNY
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)

Back Testing Results:

Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Performances of real portfolio
Top Ranked Predictable Companies & What is Predictability Rank?

$34.32     0.1(0.29%) 3:59PM EST
Fair Value Votes:$35 (4 votes; Min: $0; Max: $60)My Vote: $


Key Statistics
Please read: New Key Statistics Module, Z-Score and F-Score
Market Cap $M91,703Revenue $M47,096 Net Margin (%)18.2 Z-Score  1.5
Enterprise Value $M91,703EPS $4.0 Operating Margin %16.3 F-Score  5
P/E:(before NRI)8.5 Cash Flow Per Share $7.2 Pre-tax Margin (%)17.8Higher ROA y-yY
Price/Book1.2 10-y EBITDA Growth Rate %0Quick Ratio1.1Cash flow > EarningsY
Price/Sales2.0 5-y EBITDA Growth Rate %6.5Current Ratio1.5Lower Leverage y-yN
Price/Cash Flow4.8 y-y EBITDA Growth Rate %-22.8ROA % (ttm)7.6 Higher Current Ratio y-yN
Dividend Yield %4.4 Insider Buy (3m)0 ROE % (ttm)13.9 Less Shares Outstanding y-yN
Payout Ratio %34.0Shares Outstanding M2,682ROI % (ttm)11.2 Gross Margin Increase y-yN
Guru Trades with SNY
Exclude other managers Click to exclude managers not in the List of Gurus.
GuruDate (?) Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current SharesHistory
Whitney Tilson 2012-03-31 New Buy0.62%$35.32 - $38.92 $ 34.22-2%55000History
Ken Fisher 2012-03-31 Add 22.91%0.28%$35.32 - $38.92 $ 34.22-2%14544230History
PRIMECAP Management 2012-03-31 Add 141.26%0.08%$35.32 - $38.92 $ 34.22-2%2222692History
Third Avenue Management 2012-03-31 Add 20.16%$35.32 - $38.92 $ 34.22-2%18210History
George Soros 2011-12-31 Sold Out 0.11%$31.72 - $37.45 $ 34.22-1%0History
James Barrow 2011-12-31 Add 26.83%0.08%$31.72 - $37.45 $ 34.22-1%4501475History
Third Avenue Management 2011-12-31 Reduce -27.93%0.01%$31.72 - $37.45 $ 34.22-1%15155History
HOTCHKIS & WILEY 2011-09-30 New Buy1.08%$31.5 - $40.08 $ 34.22-5%4502166History
James Barrow 2011-09-30 Add 83.96%0.13%$31.5 - $40.08 $ 34.22-5%3549200History
George Soros 2011-09-30 New Buy0.11%$31.5 - $40.08 $ 34.22-5%201400History
Dodge & Cox 2011-06-30 Add 6.63%0.16%$35.68 - $40.58 $ 34.22-10%54287695History
Ken Fisher 2011-06-30 Add 10.69%0.15%$35.68 - $40.58 $ 34.22-10%14751479History
James Barrow 2011-06-30 Add 43.65%0.05%$35.68 - $40.58 $ 34.22-10%1929300History
David Dreman 2011-06-30 Add 38.36%0.02%$35.68 - $40.58 $ 34.22-10%96767History
John Hussman 2011-06-30 Add 39.68%$35.68 - $40.58 $ 34.22-10%17600History
Number of guru portfolios checked: 76. The trades of Premium Gurus are not included unless they are in your Personalized List.

*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

Premium More recent guru trades are included for Premium Members only!!
Guru Holdings with SNY
Exclude other managers Click to exclude managers not in the List of Gurus.
Guru Portfolio Date* Change from Last Holdings Current Shares % of Shares Outstanding % of Total Assets Managed NEW!
Holding History
Whitney Tilson 2012-03-31New Buy550000%0.62%History
PRIMECAP Management 2012-03-31+141.26%22226920.08%0.13%History
Ken Fisher 2012-03-31+22.91%145442300.54%1.5%History
Third Avenue Management 2012-03-31+20.16%182100%0.02%History
David Dreman 2012-03-31+12.81%914270%0.07%History
James Barrow 2012-03-31+5.06%47293750.18%0.36%History
John Hussman 2012-03-31221000%0.02%History
Jean-Marie Eveillard 2012-03-318087620.03%0.12%History
Warren Buffett 2012-03-3140636750.15%0.21%History
HOTCHKIS & WILEY 2012-03-31-4.44%42561620.16%0.98%History
Charles Brandes 2012-03-31-7.12%43376450.16%1.5%History
Dodge & Cox 2012-03-31-7.27%496868491.85%2.5%History
NWQ Managers 2012-03-31-13.99%135657760.51%3.6%History
Insider Trades with SNY
Exclude other managers Click Here for All Insider Trades.


No Insider Trades Found!
Related Articles
Latest About This Topic On GuruFocus.com
The Best Dividends on May 7, 2012 May 04 2012 
The Best Yielding Large Cap Healthcare Dividend Stocks May 02 2012 
6 Most Promising Dividend Stocks that Big Investment Gurus Bought May 01 2012 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Questcor: A Highly Shorted Stock To Watch This Year Apr 14 2012 
A Closer Look at the Z-Score Apr 11 2012 
Forest Laboratories (FRX): Greenblatt and Graham with a Twist of Icahn and Owens Apr 02 2012 
Abbott: A Strong Play In 2012 Mar 31 2012 
The 5 Biggest Dividend Yields In Healthcare Mar 31 2012 

More From Other Websites
Reports: Sanofi, Merck Bid At Least $25 Per Share For Amylin May 25 2012
Mylan Launches Bonviva Generic May 25 2012
Abbott: Don't Miss Out On Its High Growth May 25 2012
Progenics Pharma: Several Short Term Catalysts With Good Long Term Fundamentals May 25 2012
More Generic Launches for Mylan May 24 2012
Pfizer: Don't Overlook This $22 Gem May 24 2012
Best of the Blogs, Biotech: Is an Anti-Obesity Drug Finally in Sight? May 24 2012
[video] Emerging Markets Exposure to Europe May 24 2012
[$$] EU Joins Widening Push to Find New Antibiotics May 24 2012
Lilly's GLP-1 Agonist Delivers May 23 2012
Europe: More Is Needed May 23 2012
Buying Sanofi Shares = Short Euros? May 22 2012
Investment Strategies For The Acceleration Of Diabetes Rates May 22 2012
Medivation Files Enzalutamide NDA May 22 2012
Sony is Fighting For the Playstation Vita May 22 2012
The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr.... May 22 2012
Canada Approves Osiris' Prochymal May 21 2012
Sanofi: Kiss This Stock Goodbye May 21 2012
Business Description
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Company Website
SEC Reports
Industry: Pharmaceuticals
Compare:SAN, GSK, BMY, MRK, PFE, TEVA, ABT
Personalized Check List







Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capible and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?
Notes on SNY
Summary of Fair Value Votes within 12 monthes
$35 (4 votes; Min: $0; Max: $60)  
My Vote: $

My notes about SNY:


Notes from other users:

donli 03-13-2012

$SNY: Slow Grower  Add a comment

Read more notes

quixote1 04-18-2011

iv61  Add a comment


quixote1 04-18-2011

iv61  Add a comment


Discounted Cashflow Calculation
Calculation Formula Update Here

Enter Symbol:
 
Earnings Per Share: $
  
Default value for Earning per Share is the TTM GAAP earning. Use the information at left side to adjust.

Growth Rate
In the Next
Years: %
  
The number of years in the growth stage, and the average annual growth rate. The default value for the growth rate is the average growth rate of the past 10 years. If this growth rate is high than 20% a year, it is set to 20%.
Business Predictability  
Years of Terminal Growth:
  
The number of years for terminal value calculation. The value after this is considered zero. Default is 10.
Terminal Growth Rate: %
  
After the growth stage, it is more reasonable to set the terminal growth rate at the inflation rate. The terminal growth rate must be smaller than the discount rate to make the calculation converge.
Discount Rate:
%
  
A reasonable discount rate assumption should be at least the long term average return of the stock market, which is about 11%, because investors can always invest passively in an index fund and get an average return. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 10% - 20%.
Book Value:
 $
  
Default Book Value is the tangible book value, which may underestimate or overestimate the real value
+ Growth Value:
  
  
Cumulative earnings during the growth stage discounted to current using the discount rate.
+ Terminal Value:
  
  
Cumulative earnings during the terminal stage discounted to current using the discount rate.
= Fair Value:
  
  
Intrinsic Value = Book Value + Future Earnings at Growth Stage + Terminal Value.
 
Margin Of Safety:
 
SNY on Twitter
Annual/Quarterly Reports
User Portfolios that Have SNY
  • xfv253: voted the fair value for $0 - Apr 29, 2012
  • summerbell: voted the fair value for $40 - Apr 20, 2012
  • mhova611: voted the fair value for $60 - Jul 06, 2011
  • valennabedo: voted the fair value for $61 - May 09, 2011
  • davidchulak: voted the fair value for $61 - Apr 26, 2011
  • quixote1: voted the fair value for $61 - Apr 18, 2011
  • kfh227: voted the fair value for $65 - Apr 02, 2011
  • batbeer2: voted the fair value for $35 - Aug 16, 2010
GuruFocus Affiliate Program: Earn up to $104 per referral. ( Learn More)
Free 7-day Trial